AAN 2022 | Complement inhibitor therapy for myasthenia gravis: current and future outlooks

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the current and future role of complement inhibitor therapy for patients with myasthenia gravis. Currently, complement inhibitor therapy is mainly used in patients who have failed multiple immunotherapeutics, although their indication is for generalized myasthenia gravis without restrictions. In the future, complement inhibitors should be used in earlier lines of treatment and might be used in combination with other agents. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.